☆ 4.7 Meeting Abstract

Lorlatinib in patients with ALK plus NSCLC treated beyond initial disease progression

ANNALS OF ONCOLOGY (2020)

Get Full Text
Add to Collection

Journal

ANNALS OF ONCOLOGY
Volume 31, Issue -, Pages S842-S842

Publisher

ELSEVIER
DOI: 10.1016/j.annonc.2020.08.1616

Keywords

-

Categories

Oncology

Funding

  1. Pfizer Inc.

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.